Skip to main content
. Author manuscript; available in PMC: 2009 Feb 11.
Published in final edited form as: J Autoimmun. 2007;29(2-3):174–186. doi: 10.1016/j.jaut.2007.07.005

Fig. 4.

Fig. 4

Preferential development of cross-reactive autoantibodies occurs by 8 weeks in mice receiving murine Jo-1 fragment A (MA). (A) Immunoprecipitation of 35S-methionine-labeled extracts derived from murine cells (top panel) or the human cell line K562 (lower panel) were performed with serum samples obtained 8 weeks following immunization. A control human reference serum showing cross-reactivity to mouse Jo-1 (lane 12) is shown for comparison. Protein abbreviations are identical to those used in Fig. 2. (B) Serial anti-murine and anti-human Jo-1 antibody titers were assessed via ELISA 10-56 days following MA immunization of B6.G7 mice using full length human or murine Jo-1 as substrate antigens. In the third panel, values expressed on the y axis represent ratios of anti-human Jo-1 OD450: anti-murine Jo-1 OD450. ELISA quantification of anti-murine and anti-human Jo-1 antibody responses 8 weeks following immunization shows greater diversification following immunization with MA (C). Dots represent mean OD450 values for antibody titers from individual mice immunized with MA (a, c) or HA (b, d).